Dr. John E. Poulos, M.D.
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- Brody School of Medicine at East Carolina University (1991)
- Years since graduation
- 35
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 596
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1991Medical school: Brody School of Medicine at East Carolina University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
NC license 9801021
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cape Fear Valley Medical Center Fayetteville, NC
Medical groups
- Cumberland County Hospital System Inc (574 clinicians)
- Cape Fear Valley Health Medical Group LLC (376 clinicians)
- Premier Gastroenterology PA (23 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 596
- Services billed
- 7,633
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Pathology examination of tissue using a microscope, intermediate complexity | 464 | 221 |
| Established patient office or other outpatient visit, 30-39 minutes | 344 | 235 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 150 | 150 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 92 | 90 |
| New patient office or other outpatient visit, 45-59 minutes | 73 | 73 |
| New patient office or other outpatient visit, 15-29 minutes | 70 | 70 |
| Established patient office or other outpatient visit, 20-29 minutes | 67 | 60 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 57 | 57 |
| Biopsy of large bowel using a flexible endoscope | 54 | 54 |
| Limited ultrasound scan of abdomen | 39 | 39 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Omeprazole Other prescribers in Fayetteville, NC | 188 |
| Linzess (linaclotide) Other prescribers in Fayetteville, NC | 116 |
| Rabeprazole Sodium Other prescribers in Fayetteville, NC | 92 |
| Diphenoxylate-Atropine (diphenoxylate hcl/atropine) Other prescribers in Fayetteville, NC | 30 |
| Pantoprazole Sodium Other prescribers in Fayetteville, NC | 29 |
| Mesalamine Other prescribers in Fayetteville, NC | 22 |
| Ondansetron Hcl Other prescribers in Fayetteville, NC | 21 |
| Creon (lipase/protease/amylase) Other prescribers in Fayetteville, NC | 20 |
| Famotidine Other prescribers in Fayetteville, NC | 20 |
| Humira Pen (adalimumab) Other prescribers in Fayetteville, NC | 18 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 18 companies reported 105 payments worth $85,974 in total to this clinician.
| Novo Nordisk Inc | $56,554 |
|---|---|
| AbbVie Inc. | $17,255 |
| Madrigal Pharmaceuticals | $10,268 |
| Olympus Medical Systems Corporation | $1,015 |
| Ardelyx, Inc. | $182 |
| Aimmune Therapeutics, Inc. | $177 |
| Phathom Pharmaceuticals, Inc. | $94.10 |
| Qol Medical, LLC | $83.85 |
| Compensation for services other than consulting (speaking, faculty) | $78,091 |
|---|---|
| Travel and Lodging | $3,676 |
| Food and Beverage | $2,276 |
| Consulting Fee | $1,933 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk Inc Oct 10, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $11,127 |
| Novo Nordisk Inc Nov 12, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $8,046 |
| Novo Nordisk Inc Nov 17, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $8,046 |
| Novo Nordisk Inc Nov 10, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $7,654 |
| Novo Nordisk Inc Nov 19, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $6,476 |
| Novo Nordisk Inc Nov 20, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $6,084 |
| Novo Nordisk Inc Nov 18, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $5,103 |
| AbbVie Inc. Jan 9, 2025 | Compensation for services other than consulting (speaking, faculty) LINZESS · GASTROENTEROLOGY | $4,025 |
| AbbVie Inc. Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) LINZESS · GASTROENTEROLOGY | $4,025 |
| AbbVie Inc. Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) MAVYRET · VIROLOGY | $4,025 |
All 32 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Madrigal Pharmaceuticals Dec 15, 2025 | Consulting Fee | $1,058 |
| Novo Nordisk Inc Nov 20, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $6,084 |
| Novo Nordisk Inc Nov 20, 2025 | Travel and Lodging Wegovy · Obesity · travel to Cary, NC · in-kind | $84.00 |
| Novo Nordisk Inc Nov 19, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $6,476 |
| Novo Nordisk Inc Nov 19, 2025 | Travel and Lodging Wegovy · Obesity · travel to Greenville, NC · in-kind | $639 |
| Novo Nordisk Inc Nov 18, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $5,103 |
| Novo Nordisk Inc Nov 17, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $8,046 |
| Novo Nordisk Inc Nov 17, 2025 | Travel and Lodging Wegovy · Obesity · travel to Myrtle Beach, SC · in-kind | $126 |
| AbbVie Inc. Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) MAVYRET · VIROLOGY | $4,025 |
| Novo Nordisk Inc Nov 12, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity Company’s descriptionThe reported payment reflects the amount provided to a third party employer or institution in connection with services provided by the covered recipient. Novo Nordisk Inc. does not know how much, if any, of this amount was actually received by the covered recipient. | $8,046 |
| AbbVie Inc. Nov 12, 2025 | Compensation for services other than consulting (speaking, faculty) LINZESS · GASTROENTEROLOGY | $1,438 |
| Novo Nordisk Inc Nov 12, 2025 | Travel and Lodging Wegovy · Obesity · travel to Charleston, SC · in-kind | $965 |
| Novo Nordisk Inc Nov 10, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $7,654 |
| Novo Nordisk Inc Nov 10, 2025 | Travel and Lodging Wegovy · Obesity · travel to Florence, SC · in-kind | $122 |
| AbbVie Inc. Nov 4, 2025 | Travel and Lodging LINZESS · GASTROENTEROLOGY · travel to WILSON, NC · in-kind | $70.00 |
| AbbVie Inc. Nov 4, 2025 | Travel and Lodging LINZESS · GASTROENTEROLOGY · travel to GREENVILLE, NC · in-kind | $66.50 |
| Olympus Medical Systems Corporation Oct 22, 2025 | Consulting Fee EVIS EXERA III DUODENOVIDEOSCOPE · Gastroenterology | $875 |
| Olympus Medical Systems Corporation Oct 22, 2025 | Travel and Lodging EVIS EXERA III DUODENOVIDEOSCOPE · Gastroenterology · travel to Raleigh, NC · in-kind | $140 |
| AbbVie Inc. Oct 17, 2025 | Compensation for services other than consulting (speaking, faculty) LINZESS · GASTROENTEROLOGY | $2,875 |
| AbbVie Inc. Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) LINZESS · GASTROENTEROLOGY | $4,025 |
| Novo Nordisk Inc Oct 10, 2025 | Compensation for services other than consulting (speaking, faculty) Wegovy · Obesity | $11,127 |
| Novo Nordisk Inc Oct 10, 2025 | Travel and Lodging Wegovy · Obesity · travel to Atlanta, GA · in-kind | $539 |
| Novo Nordisk Inc Oct 10, 2025 | Travel and Lodging Wegovy · Obesity · travel to Atlanta, GA · in-kind | $374 |
| Novo Nordisk Inc Oct 10, 2025 | Travel and Lodging Wegovy · Obesity · travel to Atlanta, GA · in-kind | $221 |
| AbbVie Inc. Oct 2, 2025 | Travel and Lodging LINZESS · GASTROENTEROLOGY · travel to WILSON, NC · in-kind | $213 |
| Madrigal Pharmaceuticals Jul 31, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $2,115 |
| Madrigal Pharmaceuticals Jun 11, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $1,763 |
| Madrigal Pharmaceuticals Jun 5, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $1,763 |
| Madrigal Pharmaceuticals May 13, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $1,763 |
| Madrigal Pharmaceuticals May 8, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $1,763 |
| AbbVie Inc. Jan 9, 2025 | Compensation for services other than consulting (speaking, faculty) LINZESS · GASTROENTEROLOGY | $4,025 |
| AbbVie Inc. Jan 7, 2025 | Travel and Lodging LINZESS · GASTROENTEROLOGY · travel to CINCINNATI, OH · in-kind | $117 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $158,654 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Madrigal Pharmaceuticals · Active, not recruiting · NCT04951219 - A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
Madrigal Pharmaceuticals · Active, not recruiting · NCT03900429 - Roche Cancer Screening Collection Study
Genentech, Inc. - A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
Ipsen Bioscience Inc. · Completed · NCT06383403 - A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepati…
Boehringer Ingelheim International GmbH - A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.